3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
22
Phase 1
10
Phase 1/2
9
Phase 3
4
Phase NA
1
Phase 2/3
1
Status
Active not recruiting
3
Completed
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
46
Gastrointestinal
17
Genitourinary
10
Head & Neck
4
Gynecologic
4
Breast
4
Tumor-Agnostic
1
Sarcoma
1
Other solid neoplasm
1
Conditions
Endometrial Neoplasms
2
Ovarian Neoplasms
1
Locally Advanced Cervical Cancer
1
Interventions
Paclitaxel
150
Carboplatin
110
Cisplatin
94
Bevacizumab
42
Topotecan
39
Gemcitabine
38
liposomal doxorubicin
34
Radiotherapy
29
Doxorubicin
27
Brachytherapy
26
Taxes
24
pembrolizumab
20
olaparib
20
Drug Therapy
20
Hyperthermic Intraperitoneal Chemotherapy
16
Chemotherapy, Adjuvant
16
human papillomavirus vaccine, L1 type 16, 18
15
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
Docetaxel
13
Neoadjuvant Therapy
12
Platinum
10
niraparib
9
Radiation
9
1,2-diaminocyclohexaneplatinum II citrate
9
Vaccines, Synthetic
8
Surgical Procedures, Operative
8
atezolizumab
7
Specimen Handling
7
Papillomavirus Vaccines
7
Letrozole
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
durvalumab
×
Gynecologic
×
Clear all
NCT06746116
2026-04-16
DUoENDE
AstraZeneca
Phase 3
Active not recruiting
45 enrolled
NCT04269200
2025-12-23
DUO-E
AstraZeneca
Phase 3
Active not recruiting
805 enrolled
18 charts
1 FDA
NCT03737643
2025-01-29
DUO-O
AstraZeneca
Phase 3
Active not recruiting
1,407 enrolled
1 FDA
NCT03830866
2024-07-26
CALLA
AstraZeneca
Phase 3
Completed
770 enrolled
12 charts